I suppose a better question is whether that prior determination should have happened at all
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
The honest summary is that long-term human safety data is missing and the angiogenesis mechanism is an unresolved theoretical concern
PubMed 40131143 FDA Prescribing Information for Ozempic (semaglutide), Mounjaro (tirzepatide), Victoza (liraglutide), Byetta (exenatide), Egrifta (tesamorelin), Vyleesi (bremelanotide)
The May 14 GHK-Cu update and the April 30 GLP-1 proposal are separate policy actions, but they read together as one signal: FDA is actively curating both lists, and the regulatory ceiling for peptide compounding is being lowered for some substances and held for others
B12 isnt like coffee, you most probably wont notice any reaction to it